Serum Surfactant Protein-D as Predictor of Disease Severity in Hospitalized COPD Patients

NCT07154953 | Not Yet Recruiting

• 1 other identifier: SP-D in COPD
• Study Type: observational
• Target: 75
• Locations: 0 countries
• Sites: N/A

Brief Summary

evaluation of the serum levels of surfactant protein-D (SP-D), C-reactive protein (CRP), fibrinogen, and peripheral blood neutrophilic and eosinophilic counts in patients with COPD correlation of these biomarkers with clinical, functional, and radiological parameters

Conditions

COPD

Outcome Measures

Primary Outcomes (1)

• evaluation of serum SP-D levels

  To evaluate serum SP-D levels in patients with acute COPD exacerbation admitted to ICU and ward settings

  baseline

Secondary Outcomes (1)

• • Correlation of SP-D with: o Systemic inflammatory markers (CRP, fibrinogen, eosinophils, NLR) o Symptom burden and dyspnea scores (CAT, mMRC) o Prognostic scores (DECAF, APACHE II) o Basic CT chest findings

  baseline

Study Arms (2)

patients with acute COPD exacerbation admitted to ICU

* Adults ≥40 years diagnosed with COPD based on prior diagnosis or spirometry if available. * Admission for acute exacerbation (AECOPD) in Respiratory ICU.

Diagnostic Test: Serum Surfactant Protein-D

patients with COPD admitted to ward settings

* Adults ≥40 years diagnosed with COPD based on prior diagnosis or spirometry if available. * Admission for acute exacerbation (AECOPD) in ward .

Diagnostic Test: Serum Surfactant Protein-D

Interventions

Serum Surfactant Protein-D DIAGNOSTIC_TEST

Several studies support the use of SP-D as a marker of systemic inflammation and lung tissue damage in COPD.Measuring serum SP-D could provide a valuable tool for early detection, monitoring progression, and personalizing management of COPD patients.Surfactant protein D (SP D) as a prognostic biomarker needs further studies to validate its clinical applicability

patients with COPD admitted to ward settings; patients with acute COPD exacerbation admitted to ICU

Eligibility Criteria

• Age: 40 Years - 88 Years
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Adults ≥40 years diagnosed with COPD based on prior diagnosis or spirometry if available. Admission for acute exacerbation (AECOPD) in ward or Respiratory ICU.

You may qualify if:

• Adults ≥40 years diagnosed with COPD based on prior diagnosis or spirometry if available.
• Admission for acute exacerbation (AECOPD) in ward or Respiratory ICU.

You may not qualify if:

• Active pulmonary infection unrelated to COPD (e.g. tuberculosis, fungal infections)
• Other chronic lung diseases such as asthma, interstitial lung disease, or lung cancer
• Use of systemic corticosteroids for conditions other than COPD exacerbation

Sponsors & Collaborators

• Assiut University: lead

Related Publications (2)

• Zemans RL, Jacobson S, Keene J, Kechris K, Miller BE, Tal-Singer R, Bowler RP. Multiple biomarkers predict disease severity, progression and mortality in COPD. Respir Res. 2017 Jun 13;18(1):117. doi: 10.1186/s12931-017-0597-7.

  PMID: 28610627 BACKGROUND

• He X, Ji J, Zheng D, Luo Z, Luo L, Guo L. Serum surfactant protein D as a significant biomarker for predicting occurrence, progression, acute exacerbation, and mortality in interstitial lung disease: a systematic review and meta-analysis. Front Immunol. 2025 Feb 14;16:1450798. doi: 10.3389/fimmu.2025.1450798. eCollection 2025.

  PMID: 40028331 BACKGROUND

MeSH Terms

Conditions

Pulmonary Disease, Chronic Obstructive

Condition Hierarchy (Ancestors)

Lung Diseases, Obstructive; Lung Diseases; Respiratory Tract Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• Heba Ahmed Abdelhafeez, Professor

  Assiut University

  PRINCIPAL INVESTIGATOR

• HA Abdelhafeez, Professor

  Assiut University

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Asmaa Mostafa Ahmed

CONTACT

01113907062; smsm66023@gmail.com

Heba Ahmed Abdelhafeez, Professor

CONTACT

01006268407; Heb.abdelhafeez@anu.edu.eg

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: August 27, 2025
• First Posted: September 4, 2025
• Study Start: December 1, 2025
• Primary Completion (Estimated): December 1, 2026
• Study Completion (Estimated): January 1, 2027
• Last Updated: September 10, 2025

Record last verified: 2025-08

Data Sharing

• IPD Sharing: Will not share